{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:21:10Z","timestamp":1793676070740,"version":"4.5.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinson\u2019s disease (PD), focusing on body weight regulation and neuroprotection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>GLP-1 RAs modulate insulin signaling, reduce neuroinflammation and oxidative stress, and improve mitochondrial functional mechanisms linked to neuroprotection. Clinical trials show modest but sustained improvements in motor symptoms and suggest benefits in cognition, mood, and apathy. While GLP-1 RAs induce weight loss in diabetes, their metabolic impact in normoglycaemic PD patients appears limited. However, individuals with obesity or insulin resistance may experience enhanced clinical and cognitive outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction. Their potential for disease modification and symptom relief, particularly in specific phenotypes, supports their further exploration as part of a personalized treatment approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11892-025-01606-1","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:55:55Z","timestamp":1758887755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeting Metabolic Dysfunction in Parkinson\u2019s Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection"],"prefix":"10.1007","volume":"25","author":[{"given":"Iciar","family":"Aviles-Olmos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Espinoza-Vinces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre Rogel","family":"Portugal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rosario","family":"Luquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1606_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/mds.26868","volume":"32","author":"E De Pablo-Fernandez","year":"2017","unstructured":"De Pablo-Fernandez E, Courtney R, Holton JL, Warner TT. Hypothalamic \u03b1-synuclein and its relation to weight loss and autonomic symptoms in parkinson\u2019s disease. Mov Disord. 2017;32:296\u20138.","journal-title":"Mov Disord"},{"key":"1606_CR2","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1073\/pnas.93.10.4565","volume":"93","author":"S Przedborski","year":"1996","unstructured":"Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A. 1996;93:4565\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1606_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/ars.2008.2247","volume":"11","author":"AR Esteves","year":"2009","unstructured":"Esteves AR, Ardu\u00edno DM, Swerdlow RH, Oliveira CR, Cardoso SM. Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson\u2019s disease cybrids. Antioxid Redox Signal. 2009;11:439\u201348.","journal-title":"Antioxid Redox Signal"},{"key":"1606_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in lewy bodies. Nature. 1997;388:839\u201340.","journal-title":"Nature"},{"key":"1606_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1096\/fj.04-2751com","volume":"19","author":"W Zhang","year":"2005","unstructured":"Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in parkinson\u2019s disease. FASEB J. 2005;19:533\u201342.","journal-title":"FASEB J"},{"key":"1606_CR6","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2337\/dc10-1922","volume":"34","author":"Q Xu","year":"2011","unstructured":"Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, Schatzkin A, et al. Diabetes and risk of Parkinson\u2019s disease. Diabetes Care. 2011;34:910\u20135.","journal-title":"Diabetes Care"},{"key":"1606_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2011.12.008","volume":"315","author":"D Bosco","year":"2012","unstructured":"Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Dementia is associated with insulin resistance in patients with Parkinson\u2019s disease. J Neurol Sci. 2012;315:39\u201343.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1606_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12268","volume":"8","author":"CH N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, M\u00f8ller DV, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2022;8(1):e12268.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"1606_CR9","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1172\/JCI78371","volume":"124","author":"LL Baggio","year":"2014","unstructured":"Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124:4223\u20136.","journal-title":"J Clin Invest"},{"key":"1606_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10787-017-0331-6","volume":"25","author":"GA Badawi","year":"2017","unstructured":"Badawi GA, Abd El Fattah MA, Zaki HF, El Sayed MI. Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced parkinson\u2019s disease. Inflammopharmacology. 2017;25:369\u201382.","journal-title":"Inflammopharmacology"},{"key":"1606_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/WNR.0000000000000548","volume":"27","author":"L Cao","year":"2016","unstructured":"Cao L, Li D, Feng P, Li L, Xue GF, Li G, et al. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of parkinson\u2019s disease by reducing chronic inflammation in the brain. Neuroreport. 2016;27:384\u201391.","journal-title":"Neuroreport"},{"key":"1606_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI990","volume":"101","author":"A Flint","year":"1998","unstructured":"Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515\u201320.","journal-title":"J Clin Invest"},{"key":"1606_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","volume":"62","author":"OG Kolterman","year":"2005","unstructured":"Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm. 2005;62:173\u201381.","journal-title":"Am J Health-Syst Pharm"},{"key":"1606_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jamda.2019.11.019","volume":"21","author":"R Kim","year":"2020","unstructured":"Kim R, Jun JS. Impact of overweight and obesity on functional and clinical outcomes of early Parkinson\u2019s disease. J Am Med Dir Assoc. 2020;21:697\u2013700.","journal-title":"J Am Med Dir Assoc"},{"key":"1606_CR15","doi-asserted-by":"publisher","first-page":"7096","DOI":"10.1007\/s12035-016-0193-8","volume":"54","author":"CA Martin-Jim\u00e9nez","year":"2017","unstructured":"Martin-Jim\u00e9nez CA, Gait\u00e1n-Vaca DM, Echeverria V, Gonz\u00e1lez J, Barreto GE. Relationship between obesity, Alzheimer\u2019s disease, and Parkinson\u2019s disease: an astrocentric view. Mol Neurobiol. 2017;54:7096\u2013115.","journal-title":"Mol Neurobiol"},{"key":"1606_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0057986","volume":"8","author":"JM Sheard","year":"2013","unstructured":"Sheard JM, Ash S, Mellick GD, Silburn PA, Kerr GK. Markers of disease severity are associated with malnutrition in Parkinson\u2019s disease. PLoS ONE. 2013;8:1\u20138.","journal-title":"PLoS ONE"},{"key":"1606_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2982.2006.00780.x","volume":"18","author":"O Goetze","year":"2006","unstructured":"Goetze O, Nikodem AB, Wiezcorek J, Banasch M, Przuntek H, Mueller T, et al. Predictors of gastric emptying in Parkinson\u2019s disease. Neurogastroenterol Motil. 2006;18:369\u201375.","journal-title":"Neurogastroenterol Motil"},{"key":"1606_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26557","volume":"10","author":"W Huang","year":"2024","unstructured":"Huang W, Xiao Y, Zhang L, Liu H. Association between a body shape index and Parkinson\u2019s disease: a large cross-sectional study from NHANES. Heliyon. 2024;10:e26557.","journal-title":"Heliyon"},{"key":"1606_CR19","doi-asserted-by":"publisher","first-page":"e1002314","DOI":"10.1371\/journal.pmed.1002314","volume":"14","author":"AJ Noyce","year":"2017","unstructured":"Noyce AJ, Kia DA, Hemani G, Nicolas A, Price TR, De Pablo-Fernandez E, et al. Estimating the causal influence of body mass index on risk of Parkinson disease: a Mendelian randomisation study. PLoS Med. 2017;14:e1002314.","journal-title":"PLoS Med"},{"issue":"2","key":"1606_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/mds.27922","volume":"35","author":"SM Jeong","year":"2020","unstructured":"Jeong SM, Han K, Kim D, Rhee SY, Jang W, Shin DW. Body mass index, diabetes, and the risk of Parkinson\u2019s disease. Mov Disord. 2020;35(2):236\u201344.","journal-title":"Mov Disord"},{"issue":"7","key":"1606_CR21","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"1606_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.parkreldis.2006.12.010","volume":"13","author":"MC Fern\u00e1ndez","year":"2007","unstructured":"Fern\u00e1ndez MC, Parisi MS, D\u00edaz SP, Mastaglia SR, Deferrari JM, Seijo M, et al. A pilot study on the impact of body composition on bone and mineral metabolism in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13:355\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1606_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1600-0404.2004.00307.x","volume":"110","author":"B Loref\u00e4lt","year":"2004","unstructured":"Loref\u00e4lt B, Ganowiak W, P\u00e5lhagen S, Toss G, Unosson M, Gran\u00e9rus AK. Factors of importance for weight loss in elderly patients with Parkinson\u2019s disease. Acta Neurol Scand. 2004;110(3):180\u20137.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"1606_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000091825","volume":"52","author":"B Loref\u00e4t","year":"2006","unstructured":"Loref\u00e4t B, Ganowiak W, Wissing U, Gran\u00e9rus AK, Unosson M. Food habits and intake of nutrients in elderly patients with parkinson\u2019s disease. Gerontology. 2006;52(3):160\u20138.","journal-title":"Gerontology"},{"issue":"4","key":"1606_CR25","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2337\/dc06-2011","volume":"30","author":"G Hu","year":"2007","unstructured":"Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson\u2019s disease. Diabetes Care. 2007;30(4):842\u20137.","journal-title":"Diabetes Care"},{"issue":"5","key":"1606_CR26","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2337\/dc10-1333","volume":"34","author":"E Schernhammer","year":"2011","unstructured":"Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing parkinson\u2019s disease in Denmark. Diabetes Care. 2011;34(5):1102\u20138.","journal-title":"Diabetes Care"},{"issue":"19","key":"1606_CR27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1212\/WNL.0b013e3182553cc9","volume":"78","author":"E Cereda","year":"2012","unstructured":"Cereda E, Barichella M, Cassani E, Caccialanza R, Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology. 2012;78(19):1507\u201311.","journal-title":"Neurology"},{"issue":"6","key":"1606_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","volume":"18","author":"ML Wahlqvist","year":"2012","unstructured":"Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of parkinson\u2019s disease occurring with type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord. 2012;18(6):753\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"1606_CR29","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","volume":"143","author":"R Brauer","year":"2020","unstructured":"Brauer R, Wei L, Ma T, Arah OA, Nielsen J, Mellemkjaer L, et al. Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes. Brain. 2020;143(10):3067\u201376.","journal-title":"Brain"},{"key":"1606_CR30","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/mds.29992","volume":"39","author":"H Tang","year":"2024","unstructured":"Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Wang F, et al. Glucagon-like peptide-1 receptor agonists and risk of parkinson\u2019s disease in patients with type 2 diabetes: a population-based cohort study. Mov Disord. 2024;39:1960\u201370.","journal-title":"Mov Disord"},{"key":"1606_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2337\/diabetes.51.2.424","volume":"51","author":"CB Juhl","year":"2002","unstructured":"Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agers\u00f8 H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002;51:424\u20139.","journal-title":"Diabetes"},{"key":"1606_CR32","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664\u201375.","journal-title":"Lancet"},{"issue":"Pt 2","key":"1606_CR33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/brain\/aws009","volume":"136","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection. Brain. 2013;136(Pt 2):374\u201384.","journal-title":"Brain"},{"key":"1606_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2025;405:627\u201336.","journal-title":"Lancet"},{"key":"1606_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322.","journal-title":"N Engl J Med"},{"issue":"9309","key":"1606_CR36","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824\u201330.","journal-title":"Lancet"},{"issue":"1\u20132","key":"1606_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.regpep.2003.11.003","volume":"118","author":"MA Nauck","year":"2004","unstructured":"Nauck MA, Kleine N, Orskov C, et al. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004;118(1\u20132):89\u201397.","journal-title":"Regul Pept"},{"issue":"5","key":"1606_CR38","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"RA DeFronzo","year":"2005","unstructured":"DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092\u2013100.","journal-title":"Diabetes Care"},{"key":"1606_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, Sargin M, Karsb\u00f8l JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1606_CR40","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1073\/pnas.0806720106","volume":"106","author":"Y Li","year":"2009","unstructured":"Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and parkinsonism. Proc Natl Acad Sci U S A. 2009;106:1285\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1606_CR41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","volume":"4","author":"SC Cork","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015;4(10):718\u201331.","journal-title":"Mol Metab"},{"key":"1606_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","volume":"4","author":"B Yusta","year":"2006","unstructured":"Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, et al. GLP-1 receptor activation improves beta cell function and survival following induction of Endoplasmic reticulum stress. Cell Metab. 2006;4:391\u2013406.","journal-title":"Cell Metab"},{"issue":"4587","key":"1606_CR43","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979\u201380.","journal-title":"Science"},{"key":"1606_CR44","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1126\/science.290.5492.767","volume":"290","author":"JH Kordower","year":"2000","unstructured":"Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of parkinson\u2019s disease. Science. 2000;290:767\u201373.","journal-title":"Science"},{"key":"1606_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12929-024-01025-6","volume":"31","author":"V Wang","year":"2024","unstructured":"Wang V, Tseng KY, Kuo TT, Huang EY-K, Lan KL, Chen ZR, et al. Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in mitopark mice. J Biomed Sci. 2024;31:38.","journal-title":"J Biomed Sci"},{"key":"1606_CR46","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1021\/acsptsci.1c00013","volume":"4","author":"V Wang","year":"2021","unstructured":"Wang V, Kuo TT, Huang EY, Ma KH, Chou YC, Fu ZY, et al. Sustained release GLP-1 agonist PT320 delays disease progression in a mouse model of parkinson\u2019s disease. ACS Pharmacol Transl Sci. 2021;4:858\u201369.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1606_CR47","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12640-021-00460-9","volume":"40","author":"P Wu","year":"2022","unstructured":"Wu P, Dong Y, Chen J, Guan T, Cao B, Zhang Y, et al. Liraglutide regulates mitochondrial quality control system through PGC-1\u03b1 in a mouse model of parkinson\u2019s disease. Neurotox Res. 2022;40:286\u201397.","journal-title":"Neurotox Res"},{"issue":"2","key":"1606_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11011-021-00879-1","volume":"37","author":"B Cao","year":"2022","unstructured":"Cao B, Zhang YQ, Chen JH, Wu PY, Dong YX, Wang YQ. Neuroprotective effects of liraglutide against inflammation through the AMPK\/NF-\u03baB pathway in a mouse model of parkinson\u2019s disease. Metab Brain Dis. 2022;37(2):451\u201362.","journal-title":"Metab Brain Dis"},{"key":"1606_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2024.115001","volume":"383","author":"Y Qi","year":"2025","unstructured":"Qi Y, Dong Y, Chen J, Xie S, Ma X, Yu X, et al. Lactiplantibacillus plantarum SG5 inhibits neuroinflammation in MPTP-induced PD mice through GLP-1\/PGC-1\u03b1 pathway. Exp Neurol. 2025;383:115001.","journal-title":"Exp Neurol"},{"key":"1606_CR50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","volume":"812","author":"Z Yuan","year":"2017","unstructured":"Yuan Z, Li D, Feng P, Xue G, Ji C, Li G, et al. A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of parkinson\u2019s disease. Eur J Pharmacol. 2017;812:82\u201390.","journal-title":"Eur J Pharmacol"},{"key":"1606_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neurobiolaging.2017.12.009","volume":"64","author":"M Bomba","year":"2018","unstructured":"Bomba M, Granzotto A, Castelli V, Massetti N, Silvestri E, Canzoniero LMT, et al. Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neurobiol Aging. 2018;64:33\u201343.","journal-title":"Neurobiol Aging"},{"key":"1606_CR52","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.neuropharm.2017.02.013","volume":"117","author":"J Jalewa","year":"2017","unstructured":"Jalewa J, Sharma MK, Gengler S, H\u00f6lscher C. A novel GLP-1\/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of parkinson\u2019s disease. Neuropharmacology. 2017;117:238\u201348. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.02.013.","journal-title":"Neuropharmacology"},{"key":"1606_CR53","doi-asserted-by":"publisher","first-page":"1428817","DOI":"10.1155\/2022\/1428817","volume":"2022","author":"L Zhang","year":"2022","unstructured":"Zhang L, Li C, Zhang Z, Zhang Z, Jin QQ, Li L, H\u00f6lscher C. DA5-CH and semaglutide protect against neurodegeneration and reduce \u03b1-Synuclein levels in the 6-OHDA parkinson\u2019s disease rat model. Parkinsons Dis. 2022;2022:1428817.","journal-title":"Parkinsons Dis"},{"key":"1606_CR54","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Invest. 2013;123:2730\u20136.","journal-title":"J Clin Invest"},{"key":"1606_CR55","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Malt\u00eate D, Derkinderen P, Hou\u00e9to JL, et al. Trial of lixisenatide in early parkinson\u2019s disease. N Engl J Med. 2024;390:1176\u201385.","journal-title":"N Engl J Med"},{"key":"1606_CR56","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1212\/WNL.98.18_supplement.3068","volume":"98","author":"C Malatt","year":"2022","unstructured":"Malatt C, Wu T, Bresee C, Hogg E, Wertheimer J, Tan E, et al. Liraglutide improves non-motor function and activities of daily living in patients with parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial (P9-11.005). Neurology. 2022;98:3068.","journal-title":"Neurology"},{"key":"1606_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23:37\u201345.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1606_CR58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in parkinson\u2019s disease. J Parkinsons Dis. 2014;4(3):337\u201344.","journal-title":"J Parkinsons Dis"},{"key":"1606_CR59","doi-asserted-by":"publisher","first-page":"102726","DOI":"10.1016\/j.eclinm.2024.102726","volume":"74","author":"R De Giorgi","year":"2024","unstructured":"De Giorgi R, Koychev I, Adler AI, Cowen PJ, Harmer CJ, Harrison PJ, et al. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. EClinicalMedicine. 2024;74:102726.","journal-title":"EClinicalMedicine"},{"key":"1606_CR60","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","volume":"76","author":"D Athauda","year":"2019","unstructured":"Athauda D, Gulyani S, Karnati H, Li Y, Tweedie D, Mustapic M, et al. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the Exenatide-PD trial. JAMA Neurol. 2019;76:420\u20139.","journal-title":"JAMA Neurol"},{"key":"1606_CR61","doi-asserted-by":"publisher","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","volume":"90","author":"G Pagano","year":"2018","unstructured":"Pagano G, Polychronis S, Wilson H, Giordano B, Ferrara N, Niccolini F, et al. Diabetes mellitus and Parkinson disease. Neurology. 2018;90:e1654\u201362.","journal-title":"Neurology"},{"key":"1606_CR62","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/ejn.14096","volume":"49","author":"D Athauda","year":"2019","unstructured":"Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I, et al. Post hoc analysis of the Exenatide-PD trial\u2014factors that predict response. Eur J Neurosci. 2019;49:410\u201321.","journal-title":"Eur J Neurosci"},{"key":"1606_CR63","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JPD-181329","volume":"8","author":"D Athauda","year":"2018","unstructured":"Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene SS, et al. What effects might exenatide have on non-motor symptoms in parkinson\u2019s disease: a post hoc analysis. J Parkinsons Dis. 2018;8:247\u201358.","journal-title":"J Parkinsons Dis"},{"key":"1606_CR64","doi-asserted-by":"publisher","first-page":"15430","DOI":"10.1073\/pnas.0904944106","volume":"106","author":"E Fabbrini","year":"2009","unstructured":"Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106:15430\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1606_CR65","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0026-0495(00)80010-4","volume":"49","author":"BH Goodpaster","year":"2000","unstructured":"Goodpaster BH, Theriault R, Watkins SC, Kelley DE. Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism. 2000;49:467\u201372.","journal-title":"Metabolism"},{"key":"1606_CR66","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1161\/CIRCULATIONAHA.107.743062","volume":"117","author":"GA Rosito","year":"2008","unstructured":"Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation. 2008;117:605\u201313.","journal-title":"Circulation"},{"key":"1606_CR67","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1172\/JCI59660","volume":"122","author":"JP Thaler","year":"2012","unstructured":"Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2012;122:153\u201362.","journal-title":"J Clin Invest"},{"key":"1606_CR68","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1161\/HYPERTENSIONAHA.110.157370","volume":"56","author":"HL Chughtai","year":"2010","unstructured":"Chughtai HL, Morgan TM, Rocco M, Stacey B, Brinkley TE, Ding J, et al. Renal sinus fat and poor blood pressure control in middle-aged and elderly individuals at risk for cardiovascular events. Hypertension. 2010;56:901\u20136.","journal-title":"Hypertension"},{"key":"1606_CR69","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.2337\/dc07-0326","volume":"30","author":"ME Tushuizen","year":"2007","unstructured":"Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care. 2007;30:2916\u201321.","journal-title":"Diabetes Care"},{"key":"1606_CR70","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12020-011-9445-6","volume":"40","author":"C Davenport","year":"2011","unstructured":"Davenport C, Hishmeh S, Choudhury S, Giles T, Meeran K. The prevalence of adrenal incidentaloma in routine clinical practice. Endocrine. 2011;40:80\u20133.","journal-title":"Endocrine"},{"key":"1606_CR71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/oby.2010.106","volume":"19","author":"MA Bredella","year":"2011","unstructured":"Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, et al. Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. Obesity. 2011;19:49\u201353.","journal-title":"Obesity"},{"key":"1606_CR72","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390.","journal-title":"Lancet"},{"key":"1606_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123328","volume":"361","author":"Y Luo","year":"2025","unstructured":"Luo Y, Li JE, Zeng H, Zhang Y, Yang S, Liu J. Semaglutide alleviates the pancreatic \u03b2 cell function via the METTL14 signaling and modulating gut microbiota in type 2 diabetes mellitus mice. Life Sci. 2025;361:123328.","journal-title":"Life Sci"},{"key":"1606_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121502","volume":"319","author":"LEM Cardoso","year":"2023","unstructured":"Cardoso LEM, Marinho TS, Martins FF, Aguila MB, Mandarim-de-Lacerda CA. Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice. Life Sci. 2023;319:121502.","journal-title":"Life Sci"},{"key":"1606_CR75","first-page":"764","volume":"12","author":"M El-Sherbiny","year":"2022","unstructured":"El-Sherbiny M, El-Shafey M, Said E, Shaker GA. Dapagliflozin, liraglutide, and their combination attenuate diabetes mellitus-associated hepato-renal injury\u2014insight into oxidative injury\/inflammation\/apoptosis modulation. Life (Basel). 2022;12:764.","journal-title":"Life (Basel)"},{"key":"1606_CR76","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jcsm.12205","volume":"8","author":"DS Rooks","year":"2017","unstructured":"Rooks DS, Laurent D, Praestgaard J, Rasmussen S, Bartlett M, Tank\u00f3 LB. Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. J Cachexia Sarcopenia Muscle. 2017;8:727\u201334.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1606_CR77","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4:e2033457.","journal-title":"JAMA Netw Open"},{"key":"1606_CR78","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.cmet.2025.04.018","volume":"37","author":"J Teixidor-Deulofeu","year":"2025","unstructured":"Teixidor-Deulofeu J, Blid Sk\u00f6ldheden S, Font-Giron\u00e8s F, Feje\u0161 A, Ruud J, Engstr\u00f6m Ruud L, et al. Semaglutide effects on energy balance are mediated by Adcyap1\u2009+\u2009neurons in the dorsal vagal complex. Cell Metab. 2025;37:1530\u201346.","journal-title":"Cell Metab"},{"key":"1606_CR79","doi-asserted-by":"publisher","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","volume":"5","author":"S Gabery","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-R\u00f8nne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5:e133429.","journal-title":"JCI Insight"},{"key":"1606_CR80","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1001\/jama.2023.16620","volume":"330","author":"K Ruder","year":"2023","unstructured":"Ruder K. As semaglutide\u2019s popularity soars, rare but serious adverse effects are emerging. JAMA. 2023;330:2140\u20132.","journal-title":"JAMA"},{"key":"1606_CR81","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819\u201337.","journal-title":"Cell Metab"},{"key":"1606_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.21016","volume":"8","author":"HT Lin","year":"2025","unstructured":"Lin HT, Tsai YF, Liao PL, Wei JC. Neurodegeneration and stroke after semaglutide and tirzepatide in patients with diabetes and obesity. JAMA Netw Open. 2025;8:e2521016.","journal-title":"JAMA Netw Open"},{"key":"1606_CR83","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1021\/acschemneuro.4c00729","volume":"16","author":"P Delvadia","year":"2025","unstructured":"Delvadia P, Dhote V, Mandloi AS, Soni R, Shah J. Dual GLP-1 and GIP agonist tirzepatide exerted neuroprotective action in a parkinson\u2019s disease rat model. ACS Chem Neurosci. 2025;16:818\u201325.","journal-title":"ACS Chem Neurosci"},{"key":"1606_CR84","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","volume":"22","author":"RA Fontanella","year":"2024","unstructured":"Fontanella RA, Ghosh P, Pesapane A, Taktaz F, Puocci A, Franzese M, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med. 2024;22:114.","journal-title":"J Transl Med"},{"key":"1606_CR85","doi-asserted-by":"publisher","first-page":"171271","DOI":"10.1016\/j.peptides.2024.171271","volume":"179","author":"S Yang","year":"2024","unstructured":"Yang S, Zhao X, Zhang Y, Tang Q, Li Y, Du Y, et al. Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP\/PS1 mice. Peptides. 2024;179:171271.","journal-title":"Peptides"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-025-01606-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-025-01606-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-025-01606-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:03:16Z","timestamp":1770296596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-025-01606-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1007\/s11892-025-01606-1","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"25 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"49"}}